The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS
TheValue of Placental Vascularization Indices and Placental Volume in Pregnancies With Antiphospholipid Syndrome for Prediction of Neonatal Outcome"
1 other identifier
observational
100
1 country
1
Brief Summary
Antiphospholipid antibodies are autoantibodies directed against phospholipid-binding proteins. Among these groups of antibodies, lupus anticoagulant (LA) and anticardiolipin antibodies (aCL)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 13, 2018
CompletedFirst Posted
Study publicly available on registry
April 23, 2018
CompletedStudy Start
First participant enrolled
April 24, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 4, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 10, 2020
CompletedJanuary 27, 2020
January 1, 2020
2.4 years
April 13, 2018
January 24, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
The number of participants who will have impaired placental doppler indices
within 2 months
Study Arms (2)
antiphospholipid group
pregnant ladies in the third trimester who have antiphospholipid syndrome
control group
pregnant ladies in the third trimester who have no medical disorders with pregnancy
Interventions
ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
Eligibility Criteria
Singleton pregnancy. * Gestational age of 34-37 weeks. * Pregnant women with antiphospholipid syndrome
You may qualify if:
- Singleton pregnancy.
- Gestational age of 34-37 weeks.
- Pregnant women with antiphospholipid syndrome
You may not qualify if:
- Twin or multiple pregnancies.
- Congenital fetal anomalies.
- Gestational age of less than 34.
- Gestational age of more than 37.
- Women with placental or umbilical artery anomalies.
- Antepartum hemorrhage (placental abruption, placenta previa and vasa previa).
- Posterior placenta.
- History of rupture of membrane.
- Patient refusal or fall outs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aljazeera Hospitallead
- Cairo Universitycollaborator
Study Sites (1)
Algazeerah
Giza, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mahmoud Alalfy
Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Researcher , National Research centre and Specialist of Obstetrics and Gynecology in Aljazeerah hospital
Study Record Dates
First Submitted
April 13, 2018
First Posted
April 23, 2018
Study Start
April 24, 2018
Primary Completion
September 4, 2020
Study Completion
October 10, 2020
Last Updated
January 27, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will not share
The research data will be published